Malta - English - Medicines Authority

smithkline beecham limited - mumps vaccine rit 4385; measles virus - schwarz strain; rubella virus - wistar ra27/3 strain - powder and solvent for solution for injection - mumps vaccine rit 4385; measles virus - schwarz strain; rubella virus - wistar ra27/3 strain - vaccines

Malta - English - Medicines Authority

glaxosmithkline biologicals s.a. rue de l'institut 89 b-1330 rixensart, belgium - varicella virus, oka strain, live, attenuated, measles virus, schwarz strain, mumps virus, jeryl lynn, level b, rubella virus, wistar ra - powder and solvent for solution for injection in pre-filled syringe - varicella virus oka strain (live, attenuated) measles virus - schwarz strain mumps virus jeryl lynn (level b) strain (live, attenuated) rubella virus wistar ra 27/3 strain (live, attenuated) - vaccines

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - influenza virus a/michigan/45/2015 (h1n1) pdm09 - like strain 15ug (a/singapore/gp1908/2015, ivr-180); influenza virus a/switzerland/8060/2017 (h3n2) like strain 15ug (a/brisbane/1/2018, nymc x-311); influenza virus b/colorado/06/2017 - like strain 15ug (b/maryland/15/2016, nymc bx-69a (victoria lineage)); influenza virus b/phuket/3073/2013 - like strain 15ug (b/phuket/3073/2013, wild type (yamagata lineage)) - suspension for injection - 0.5 ml - active: influenza virus a/michigan/45/2015 (h1n1) pdm09 - like strain 15ug (a/singapore/gp1908/2015, ivr-180) influenza virus a/switzerland/8060/2017 (h3n2) like strain 15ug (a/brisbane/1/2018, nymc x-311) influenza virus b/colorado/06/2017 - like strain 15ug (b/maryland/15/2016, nymc bx-69a (victoria lineage)) influenza virus b/phuket/3073/2013 - like strain 15ug (b/phuket/3073/2013, wild type (yamagata lineage)) excipient: d-alpha-tocopheryl acid succinate dibasic sodium phosphate dodecahydrate magnesium chloride hexahydrate monobasic potassium phosphate octoxinol polysorbate 80 potassium chloride sodium chloride water for injection - fluarix tetra is a quadrivalent vaccine indicated for active immunisation of adults and children from 6 months of age for the prevention of influenza disease caused by the influenza virus types a and b contained in the vaccine. the use of fluarix tetra should be based on official recommendations.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - influenza virus a/darwin/9/2021 (h3n2)-like strain 15ug (a/darwin/9/2021 san-010 ); influenza virus a/sydney/5/2021 (h1n1) pdm09-like strain 15ug (a/sydney/5/2021, san-013); influenza virus b/austria/1359417/2021-like strain 15ug (b/michigan/01/2021 wild type ); influenza virus b/phuket/3073/2013 - like strain 15ug (b/phuket/3073/2013 wild type ) - suspension for injection - 60 mcg - active: influenza virus a/darwin/9/2021 (h3n2)-like strain 15ug (a/darwin/9/2021 san-010 ) influenza virus a/sydney/5/2021 (h1n1) pdm09-like strain 15ug (a/sydney/5/2021, san-013) influenza virus b/austria/1359417/2021-like strain 15ug (b/michigan/01/2021 wild type ) influenza virus b/phuket/3073/2013 - like strain 15ug (b/phuket/3073/2013 wild type ) excipient: octoxinol 9 phosphate buffered saline - fluquadri is indicated for active immunisation of influenza disease caused by influenza a subtype viruses and type b viruses contained in the vaccine. fluquadri is indicated for use in adults and children 6 months and older.

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - influenza virus a/michigan/45/2015 (h1n1) pdm09 - like strain 7.5ug (a/michigan/45/2015, x-275); influenza virus a/singapore/infimh-16-0019/2016 (h3n2) - like strain 7.5ug (a/singapore/infimh-16-0019/2016, nib-104); influenza virus b/brisbane/60/2008 - like strain 7.5ug (b/brisbane/60/2008 (victoria lineage)); influenza virus b/phuket/3073/2013 - like strain 7.5ug (b/phuket/3073/2013 (yamagata lineage)) - suspension for injection - 30 mcg - active: influenza virus a/michigan/45/2015 (h1n1) pdm09 - like strain 7.5ug (a/michigan/45/2015, x-275) influenza virus a/singapore/infimh-16-0019/2016 (h3n2) - like strain 7.5ug (a/singapore/infimh-16-0019/2016, nib-104) influenza virus b/brisbane/60/2008 - like strain 7.5ug (b/brisbane/60/2008 (victoria lineage)) influenza virus b/phuket/3073/2013 - like strain 7.5ug (b/phuket/3073/2013 (yamagata lineage)) excipient: octoxinol 9 phosphate buffered saline - fluquadri junior is indicated for active immunisation of influenza disease caused by influenza a subtype viruses and type b viruses contained in the vaccine. fluquadri junior is indicated for use in children aged 6 months to 35 months inclusive.

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - influenza virus haemagglutinin, quantity: 15 microgram - injection, suspension - excipient ingredients: sodium chloride; dibasic sodium phosphate; monobasic sodium phosphate; potassium chloride; monobasic potassium phosphate; calcium chloride dihydrate; water for injections - for the prevention of influenza caused by influenza virus, types a and b contained in the vaccine. the vaccine is indicated for use only in persons aged 5 years and over. for full details regarding recommendations for influenza vaccination, please refer to the relevant national immunisation guidelines.

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - influenza virus haemagglutinin -

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - influenza virus haemagglutinin -

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - influenza virus haemagglutinin,potassium chloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - influenza virus haemagglutinin -